Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What facilitators need to know about the evidence, the protocols, the contraindications, and the backfire pattern.
External link. We are not responsible for the content.
Read more ↗More From Microdosing Institute
Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series
In a study on iboga microdosing, in all three cases, participants reported better sleep, improved mood regulation, an...
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Repeated microdosing of LSD (8 to 20 μg) may help improve daily mood, specifically increasing feelings of connection,...
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Caregivers of people with advanced cancer often find that psychedelic-assisted therapy can strengthen their relations...
Latest News
The Toads Didn’t Consent to Being Milked, Sorry
Chasing "enlightenment" at the expense of desert toads is not the flex you think it is. [...] Read More... The post T...
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the...
Weekly Psychedelic Policy Briefing – August 9, 2026
Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affai...
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
Why don’t some people respond to psychedelics? 5 Questions for psychologist Rachel Ham
Ham discusses doing interviews with clinical trial participants who didn’t experience substantial benefits.